USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA); Guam (USA); Puerto Rico (USA); Virgin Islands (USA); Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta; British Columbia; Manitoba; New Brunswick; Newfoundland and Labrador; Northwest Territories; Nova Scotia; Nunavut; Ontario; Prince Edward Island; Quebec; Saskatchewan; Yukon
Israel
International country outside of the USA, Israel and Canada.
Grants of up to $50,000 to USA, Canada, and International organizations for educational projects related to gene and gene-modified cell therapies. Funding is intended for medical education initiatives that will expand the understanding and incorporation of gene and gene-modified cell therapies into the treatment of rare diseases.
This Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The American Society of Gene + Cell Therapy and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on supporting independent medical education to increase the medical and scientific understanding of gene and gene-modified cell therapies.
Projects that will be considered for support will focus on independent medical education initiatives that will result in the measurable improvement of the medical and scientific understanding of gene and gene-modified cell therapies to help prepare multidisciplinary teams for the integration of gene and gene-modified cell therapies into the treatment armamentarium of eligible patients with a Rare Disease.
Target Audience: Members of multidisciplinary care teams for gene and gene modified cell therapies including but not limited to Pharmacists, Specialty Nurses, Genetic Counsellors, Medical Geneticists, and other Physicians.
Estimated Total Program Funding:
Estimated Size of Grant:
Apply at http://www.cybergrants.com/pfizer/knowledge.
If you have questions regarding this RFP, please direct them in writing to the Pfizer Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com) with the subject line “2023 RD G - ASGCT Gene Education.”